Live Breaking News & Updates on Insilico medicine inc

Stay informed with the latest breaking news from Insilico medicine inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Insilico medicine inc and stay connected to the pulse of your community

AI-driven research identifies pulmonary fibrosis target and inhibitor

Deep learning algorithms have enabled the discovery of molecular structures of interest in biomedicine to design treatments against aggressive diseases such as idiopathic pulmonary fibrosis (IPF). Scientists at Insilico Medicine Inc. selected a target for IPF using artificial intelligence (AI), then designed an inhibitor to block it, and tested it in vitro, in vivo, and in clinical trials.

Scientists-at-insilico-medicine-inc , Insilico-medicine , Bioworld-science , Respiratory , Insilico-medicine-inc- , Idiopathic-pulmonary-fibrosis , Tnik , Tnik-inhibitors , Artificial-intelligence , Drug-design , Rug-delivery-and-technologies

Longevity AI-biotech Gero raises $6M in series A round for aging research

“Aging is not only slow, but it is irreversible, and that is what most people have been suspecting,” Gero Pte Ltd.’s CEO Peter Fedichev recently told BioWorld. “[But] aging is not an inevitable part of human existence.” By setting limits to what science can do – and not do – for aging, the Palo Alto, Calif.- and Singapore-based generative artificial intelligence (AI) biotech Gero is trying to figure out and, at the same time help the industry, “see what is actionable, reversible and what may not be” to help people avoid “hitting their heads against the wall” when tackling aging and aging-related diseases.

Singapore , Peter-fedichev , Gero-pte-ltd , Palo-alto , Aging , Gero-pte-ltd- , Generative-ai , Aging-related-diseases , Melnichek-investments , University-of-singapore , Insilico-medicine-inc- , Altos-labs-inc-

GBC 2023: In generative AI era, collaboration key for drug discovery

Rapidly evolving artificial intelligence (AI) is effectively resetting all biopharmaceutical companies to the figurative starting line, and collaboration is a key strategy to winning the drug discovery race, an AI-based startup founder said at the Global Bio Conference (GBC) 2023.

Global-bio-conference , Ai , Artificial-intelligence , Generative-ai , Ai-based-drug-development , Drug-design , Standigm , Atomwise-inc- , Insilico-medicine-inc- , Exscientia-ltd- , Benevolentai-ltd-